-+ 0.00%
-+ 0.00%
-+ 0.00%

Tissue Dynamics, Galmed Pharmaceuticals Partner To Develop Novel Human Chronic Fibrosis Model

Benzinga·05/06/2026 11:37:40
Listen to the news

Tissue Dynamics Ltd. and Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver disease and GI oncological therapeutics, today announced a collaboration to develop a novel human chronic cardiac fibrosis model designed to accelerate the discovery and development of new Aramchol-based therapeutic approaches for complex fibrotic heart diseases.